Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2008 1
2010 1
2011 1
2012 1
2013 4
2014 4
2015 7
2016 2
2017 5
2018 4
2019 6
2020 4
2021 10
2022 12
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 22Alokail, 5BAuthor
Page 1
Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
Narita I, Tsubakihara Y, Uchiyama T, Okamura S, Oya N, Takahashi N, Gejyo F; MR13A9-4 Trial Investigators. Narita I, et al. JAMA Netw Open. 2022 May 2;5(5):e2210339. doi: 10.1001/jamanetworkopen.2022.10339. JAMA Netw Open. 2022. PMID: 35511180 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled, 4-arm phase 2 trial was conducted from February 1, 2019, to October 22, 2019, at 94 sites in Japan. Patients with moderate to severe pruritus receiving hemodialysis were enrolled. ...The …
DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled, 4-arm phase 2 trial was conducted from February 1, 201 …
Erratum.
[No authors listed] [No authors listed] Mult Scler. 2016 Oct;22(12):NP9-NP11. doi: 10.1177/1352458515585718. Epub 2015 Jun 3. Mult Scler. 2016. PMID: 26041800
Adherence to home-based balance training was highest in the exergame group.Goble et al.(24)WiiCase study. N=1, 28 year old Male. Relapsing-remitting MS since age 11. EDSS 5.0. INTERVENTION: Six-week balance training, 3x30 mins per week. ...Over first two weeks 12% decrease …
Adherence to home-based balance training was highest in the exergame group.Goble et al.(24)WiiCase study. N=1, 28 year old Male. Relapsing-r …
The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications.
Young CA, Mills R, Langdon D, Sharrack B, Majeed T, Kalra S, Footitt D, Rog D, Harrower T, Nicholas R, Woolmore J, Thorpe J, Hanemann CO, Ford H, Paling D, Ellis C, Palace J, Constantinescu C, Tennant A. Young CA, et al. J Neurol Sci. 2022 May 15;436:120188. doi: 10.1016/j.jns.2022.120188. Epub 2022 Feb 18. J Neurol Sci. 2022. PMID: 35303502
METHODS: Participants completed serial questionnaire packs, including Unidimensional Self-efficacy-MS (USE-MS) scale, for the Trajectories of Outcome in Neurological Conditions-MS (TONiC-MS) study over an average 46-month period. ...RESULTS: 5887 pwMS …
METHODS: Participants completed serial questionnaire packs, including Unidimensional Self-efficacy-MS (USE-MS) scale, for the …
Humanistic Burden of Huntington Disease: Evidence From the Huntington Disease Burden of Illness Study.
Rodriguez Santana I, Frank S, Doherty M, Willock R, Hamilton J, Hubberstey H, Stanley C, Vetter L, Winkelmann M, Dolmetsch RE, Li N, Ratsch S, Ali TM. Rodriguez Santana I, et al. Neurol Clin Pract. 2022 Dec;12(6):e172-e180. doi: 10.1212/CPJ.0000000000200095. Neurol Clin Pract. 2022. PMID: 36540140 Free PMC article.
Patient-reported outcomes included the 5-level EQ-5D version (EQ-5D-5L), Short-Form-(SF)-36 v2 (and SF-6-Dimension [SF-6D] utility), Huntington Quality of Life Instrument (H-QoL-I), and the Work Productivity and Activity Impairment Specific Health Problem. ...Partic …
Patient-reported outcomes included the 5-level EQ-5D version (EQ-5D-5L), Short-Form-(SF)-36 v2 (and SF-6-Dimension [SF-6D] uti …
Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Hümmert MW, Bütow F, Tkachenko D, Ayzenberg I, Pakeerathan T, Hellwig K, Klotz L, Häußler V, Stellmann JP, Warnke C, Goereci Y, Etgen T, Luessi F, Bronzlik P, Gingele S, Lauenstein AS, Kleiter I, Rommer PS, Paul F, Bellmann-Strobl J, Duchow A, Then Bergh F, Pul R, Walter A, Pellkofer H, Kümpfel T, Pompsch M, Kraemer M, Albrecht P, Aktas O, Ringelstein M, Senel M, Giglhuber K, Berthele A, Jarius S, Wildemann B, Trebst C; Neuromyelitis Optica Study Group (NEMOS). Hümmert MW, et al. Neurol Neuroimmunol Neuroinflamm. 2023 Jan 24;10(2):e200082. doi: 10.1212/NXI.0000000000200082. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36693760 Free PMC article.
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database. ...The reported HRQoL did not decline compared with a prepandemic assessment (m …
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clin …
Health-related quality of life of multiple sclerosis patients: a European multi-country study.
Visser LA, Louapre C, Uyl-de Groot CA, Redekop WK. Visser LA, et al. Arch Public Health. 2021 Mar 20;79(1):39. doi: 10.1186/s13690-021-00561-z. Arch Public Health. 2021. PMID: 33743785 Free PMC article.
The mean EQ-5D utility was 0.65 (SD:0.26). Cross-country differences in HRQOL were found. A common predictor of HRQOL was disability status and primary progressive MS. CONCLUSIONS: The effects of MS on HRQOL in real-world patients may be underestimated. ...
The mean EQ-5D utility was 0.65 (SD:0.26). Cross-country differences in HRQOL were found. A common predictor of HRQOL was disability …
The Burden of Migraine on Quality of Life in Chronic Rhinosinusitis.
Derbarsegian A, Adams SM, Phillips KM, Sedaghat AR. Derbarsegian A, et al. Laryngoscope. 2023 Dec;133(12):3279-3284. doi: 10.1002/lary.30662. Epub 2023 Mar 27. Laryngoscope. 2023. PMID: 36971228
METHODS: A total of 213 adult patients with CRS were recruited. All participants completed the 22-item Sinonasal Outcome Test (SNOT-22), from which total and validated nasal, ear/facial pain, sleep, and emotional subdomain scores were calculated, and the 5-dimension …
METHODS: A total of 213 adult patients with CRS were recruited. All participants completed the 22-item Sinonasal Outcome Test (SNOT- …
Complications, readmissions, reoperations and patient-reported outcomes in patients with multiple sclerosis undergoing elective spine surgery - a propensity matched analysis.
Steinle AM, Nian H, Pennings JS, Bydon M, Asher A, Archer KR, Gardocki RJ, Zuckerman SL, Stephens BF, Abtahi AM. Steinle AM, et al. Spine J. 2022 Nov;22(11):1820-1829. doi: 10.1016/j.spinee.2022.06.009. Epub 2022 Jun 30. Spine J. 2022. PMID: 35779839
STUDY DESIGN/SETTING: Retrospective review of prospectively collected data from the Quality Outcomes Database (QOD), a national, longitudinal, multicenter spine outcomes registry. PATIENT SAMPLE: For the lumbar cohort, 312 patients with MS and 46,738 patients without MS
STUDY DESIGN/SETTING: Retrospective review of prospectively collected data from the Quality Outcomes Database (QOD), a national, longitudina …
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Sinks S, Kuhelj R, Bodhinathan K, Lasky T. Ryerson LZ, et al. Mult Scler Relat Disord. 2023 Apr;72:104561. doi: 10.1016/j.msard.2023.104561. Epub 2023 Feb 11. Mult Scler Relat Disord. 2023. PMID: 36931078 Free article. Clinical Trial.
At week 72, there were no significant differences between Q6W and Q4W groups in LSM change from baseline for T25FW (0.00, P = 0.975), 9HPT (dominant [0.22, P = 0.533] or nondominant [0.09, P = 0.862] hand), or SDMT (-1.03, P = 0.194). Similarly, there were no significant d …
At week 72, there were no significant differences between Q6W and Q4W groups in LSM change from baseline for T25FW (0.00, P = 0.975), 9HPT ( …
Measuring quality of life and identifying what is important to Jordanian living with multiple sclerosis using the Arabic version of the patient-generated index.
Aburub AS, Khalil H, Al-Sharman A, El-Salem K. Aburub AS, et al. Physiother Res Int. 2021 Apr;26(2):e1893. doi: 10.1002/pri.1893. Epub 2021 Jan 15. Physiother Res Int. 2021. PMID: 33448540
METHODS: A total of 75 participants with MS completed three QOL measures; PGI, the patient determined disease steps (PDDS), and EQ-5D. ...PGI had a moderate correlation with EQ-5D and PPDS. CONCLUSION: The Arabic version of the PGI is a feasible, acceptable, …
METHODS: A total of 75 participants with MS completed three QOL measures; PGI, the patient determined disease steps (PDDS), and EQ- …
64 results